Article Information
History
- January 19, 2022.
Article Versions
- Version 1 (January 1, 2022 - 14:48).
- Version 2 (January 4, 2022 - 10:18).
- Version 3 (January 12, 2022 - 11:30).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
REVISION SUMMARY
Disclosures: None.
Funding: This project was supported by the Houston Methodist Academic Institute Infectious Diseases Fund; and in part with funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076 (J.J.D.).
Tables and figures updated with additional data.
Author Information
- Paul A. Christensen*,†,‡,§,
- Randall J. Olsen*,†,‡,§,
- S. Wesley Long*,†,‡,§,
- Richard Snehal†,
- James J. Davis¶,**,
- Matthew Ojeda Saavedra†,
- Kristina Reppond†,
- Madison N. Shyer†,
- Jessica Cambric†,
- Ryan Gadd†,
- Rashi M. Thakur†,
- Akanksha Batajoo†,
- Regan Mangham†,
- Sindy Pena†,
- Trina Trinh†,
- Jacob C. Kinskey†,
- Guy Williams†,
- Robert Olson¶,**,
- Jimmy Gollihar‡ and
- James M. Musser†,‡,§,††
- †Laboratory of Human Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
- ‡Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
- §Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
- ¶Consortium for Advanced Science and Engineering, University of Chicago, Chicago, Illinois
- **Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, Illinois
- ↵††Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street, Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail: jmmusser{at}houstonmethodist.org
↵* Contributed equally;
Posted January 19, 2022.
Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas
Subject Area
Reviews and Context
3
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
30
Blogs/Media
Author Videos